For example, one study found deletions of 4q (TET2 mutations) were evenly distributed between the chronic phase and MPN-BP [39], while others showed a significant association of TET2 mutations with an increased risk of leukemic progression [24,34]. This evidence concerns the gene TET2 and myeloproliferative neoplasm.